Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date Qi Zhao Leading Article 08 January 2020 Pages: 111 - 119
Anti-HIV-1 Antibodies: An Update Wanwisa PromsoteMegan E. DeMouthAmarendra Pegu Leading Article 09 March 2020 Pages: 121 - 132
Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline Kalliopi KlavdianouArgyro LazariniAntonis Fanouriakis Leading Article 30 January 2020 Pages: 133 - 147
Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria Bruno FattizzoAustin G. Kulasekararaj Leading Article 08 January 2020 Pages: 149 - 158
Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price! Binita DuttaIsabelle HuysSteven Simoens Review Article Open access 02 December 2019 Pages: 159 - 170
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL) Jeff P. SharmanAnna Marina LiberatiIgor Aurer Original Research Article Open access 09 December 2019 Pages: 171 - 181
Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study Vikram Muralidhar HaridasRahul KattaSuresh Kankanwadi Original Research Article Open access 12 February 2020 Pages: 183 - 196
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial Stanley B. CohenSebastiao C. RadominskiRieke Alten Original Research Article Open access 14 January 2020 Pages: 197 - 207
Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study Srishti JoshiAnurag S. Rathore Original Research Article 23 January 2020 Pages: 209 - 223
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars Hans C. EbbersBjørn FehrmannMourad Farouk Rezk Original Research Article Open access 10 January 2020 Pages: 225 - 233
Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis Arnold LeeLesley J. Scott Adis Drug Evaluation 23 March 2020 Pages: 235 - 244
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus Sheridan M. Hoy Adis Drug Evaluation Open access 25 March 2020 Pages: 245 - 251
Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents Vibeke StrandJoao GonçalvesJohn D. Isaacs Correction Open access 26 February 2020 Pages: 253 - 253
